Spectrum Pharmaceuticals (NASDAQ:SPPI) presentation at the BIOCOM Conference yesterday is worth listening.
From my view, it seems like SPPI's CEO Raj had a positive outlook for Zevalin's potential with respect to future sales.
I like what I heard and will remain invested in the company over the long-term.
I hedge long positions with put options.
Disclosure: Long SPPI.